Krystal Biotech IncKRYS
Price$325.31Intrinsic value$377.6316% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $440.5M+51.6% YoYTTM through 30 Jun 2026
Net Income $241.5M+170.8% YoYTTM through 30 Jun 2026
Free Cash Flow $257.8MTTM through 30 Jun 2026

Margins

Current
Gross Margin94.6%
EBITDA Margin45.8%
Operating Margin46.2%
Net Margin54.8%

Returns

18.4%ROE
16.1%ROA
17.6%ROIC

Balance Sheet Health

Debt / Equity0.00x
Current Ratio9.50x
Net Debt-$823.4Mnet cash position
Cash & Equivalents$427.7M

Quality Metrics

Altman Z-Score45.63
Piotroski F-Score5 / 9
FCF Margin58.5%
Rule of 4074.9
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'21'22'23'24'25
FY2025: $389.1M
Diluted EPS$7.98TTM
'20'21'22'23'24'25
FY2025: $6.84

Dividend

No dividend

Capital Allocation

R&D Spend$59.2M
Capex Intensity3.3%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.